Investors / United States / Bios Partners
Bios Partners
Venture capital · Fort Worth, TX, United States · North America
Bios Partners is a venture capital firm that invests in biotechnology companies in overlooked and under-invested markets in the Central United States. It also works actively with management teams to fill operational gaps and help bring science to market.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsoncologycell therapygene therapymedical devices
Your fit with Bios Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBios Partners lists 13 checked portfolio companies on its own site and is named in 1 funding round. Its largest themes are Healthcare & Biotech (79%), AI & Machine Learning (7%) and Cybersecurity (7%). 100% of its companies are based in United States. It invests most often alongside Michigan Capital Network, ExSight Ventures and Green Park & Golf Ventures.
Counts come from funding rounds that name Bios Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Bios Partners' whole history. Rounds on record name 1 company; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundBios Partners does not state its stages on its site, so only what it does is shown.
The rounds that name Bios Partners do not give a stage.
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 93th | 79% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Michigan Capital Network | 3 |
| ExSight Ventures | 2 |
| Green Park & Golf Ventures | 2 |
| 3E Bioventures Capital | 1 |
| Accelerate Blue Fund | 1 |
| BioRock Ventures | 1 |
| Biovision Ventures | 1 |
| Bling Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 79% | 15% |
| AI & Machine Learning | 7% | 18% |
| Cybersecurity | 7% | 4% |
| Food & Agriculture | 7% | 3% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Michigan Capital Network
Compare Bios Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Bios Partners| Date | Company | Stage |
|---|---|---|
| 18 Feb 2026 | Round |
Round details for Bios Partners
Amounts, full round histories and every co-investor in Bios Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company produces and sells mushroom-based products that can be combined with ground meat or poultry for a more sustainable and nutritious culinary experience. | Food & Agriculture | Feb 2026Round | Funding round | |
| Actuate develops and provides AI video analytics software for security operations | AI & Machine LearningCybersecurity | Portfolio page | ||
| The company develops therapies designed to help patients and caregivers living with age-related neurodegenerative diseases. | Healthcare & Biotech | Portfolio page | ||
| i-Lumen Scientific develops a bioelectric therapy intended to restore retinal electrophysiology in patients with intermediate to advanced dry AMD. | Healthcare & Biotech | Portfolio page | ||
| Immusoft engineers B cells as biofactories for therapeutic protein delivery | Healthcare & Biotech | Portfolio page | ||
| IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for solid and hematological tumors. | Healthcare & Biotech | Portfolio page | ||
| Lantern Pharma is developing precision oncology therapies using artificial intelligence, genomics, and machine learning | Healthcare & Biotech | Portfolio page | ||
| ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions | Healthcare & Biotech | Portfolio page | ||
| Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing new therapies for the treatment of inherited retinal diseases and other retinal and refractive disorders. | Healthcare & Biotech | Portfolio page | ||
| Renibus is a clinical stage biopharmaceutical company developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| Stream Biomedical is advancing a new class of biologics that restores brain health by addressing the cause of neurodegenerative diseases, not the symptoms. | Healthcare & Biotech | Portfolio page | ||
| Taysha Gene Therapies develops gene therapies to treat diseases of the central nervous system caused by the mutation of a single gene | Healthcare & Biotech | Portfolio page | ||
| Trefoil develops therapies for corneal diseases based on the regenerative properties of corneal cells. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- biospartners.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 18 Feb 2026
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Bios Partners' profile as data
Pull Bios Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/biospartners.com
# also
GET /v1/firms/biospartners.com/portfolio
GET /v1/firms/biospartners.com/coinvestors
GET /v1/firms/biospartners.com/news